CANDEL THERAPEUTICS, INC. Fair Value Adjustment of Warrants
CANDEL THERAPEUTICS, INC. (CADL) reported Fair Value Adjustment of Warrants of $12.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $12.28M.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$7.64M.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was $13.52M, a 131.81% increase year-over-year.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$1.15M, a 169.96% decline year-over-year.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2025 was -$8.20M, a 139.41% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2024 was $20.80M.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2023 was -$966.00K.
- CANDEL THERAPEUTICS, INC. fair value adjustment of warrants for fiscal 2022 was -$16.37M, a 243.33% decline from fiscal 2021.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.28M 10-Q · filed 2026-08-13 | $4.63M 10-Q · filed 2026-08-13 | $18.15M derived: sum of 3 quarters · filed 2026-08-13 | $17.01M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$7.64M 10-Q · filed 2026-05-14 | $5.88M derived: sum of 2 quarters · filed 2026-05-14 | $4.73M derived: sum of 3 quarters · filed 2026-05-14 | -$961.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $12.37M derived: sum of 2 quarters · filed 2026-03-12 | $6.68M derived: sum of 3 quarters · filed 2026-08-13 | -$8.20M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.15M 10-Q · filed 2025-11-13 | -$6.84M derived: sum of 2 quarters · filed 2026-08-13 | -$21.72M 10-Q · filed 2025-11-13 | -$15.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$5.69M 10-Q · filed 2026-08-13 | -$20.57M 10-Q · filed 2026-08-13 | -$14.74M derived: sum of 3 quarters · filed 2026-08-13 | -$13.10M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$14.88M 10-Q · filed 2026-05-14 | -$9.05M derived: sum of 2 quarters · filed 2026-05-14 | -$7.41M derived: sum of 3 quarters · filed 2026-05-14 | $5.93M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $7.47M derived: sum of 2 quarters · filed 2026-03-12 | $20.81M derived: sum of 3 quarters · filed 2026-03-12 | $20.80M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.64M 10-Q · filed 2025-11-13 | $14.98M derived: sum of 2 quarters · filed 2025-11-13 | $14.97M 10-Q · filed 2025-11-13 | $15.45M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $13.34M 10-Q · filed 2025-08-14 | $13.33M 10-Q · filed 2025-08-14 | $13.81M derived: sum of 3 quarters · filed 2025-08-14 | $13.23M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$7.00K 10-Q · filed 2025-05-13 | $476.00K derived: sum of 2 quarters · filed 2025-05-13 | -$105.00K derived: sum of 3 quarters · filed 2025-05-13 | -$249.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$98.00K derived: sum of 2 quarters · filed 2025-03-13 | -$242.00K derived: sum of 3 quarters · filed 2025-03-13 | -$966.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$581.00K 10-Q · filed 2024-11-14 | -$725.00K derived: sum of 2 quarters · filed 2024-11-14 | -$1.45M 10-Q · filed 2024-11-14 | -$4.19M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$144.00K 10-Q · filed 2024-08-13 | -$868.00K 10-Q · filed 2024-08-13 | -$3.61M derived: sum of 3 quarters · filed 2024-08-13 | -$3.98M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$724.00K 10-Q · filed 2024-05-14 | -$3.47M derived: sum of 2 quarters · filed 2024-05-14 | -$3.84M derived: sum of 3 quarters · filed 2024-05-14 | -$8.81M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$3.11M derived: sum of 2 quarters · filed 2024-03-28 | -$8.08M derived: sum of 3 quarters · filed 2024-03-28 | -$16.37M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$369.00K 10-Q · filed 2023-11-09 | -$5.34M derived: sum of 2 quarters · filed 2023-11-09 | -$13.63M 10-Q · filed 2023-11-09 | -$22.82M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$4.97M 10-Q · filed 2023-08-10 | -$13.26M 10-Q · filed 2023-08-10 | -$22.45M derived: sum of 3 quarters · filed 2023-08-10 | -$14.20M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$8.29M 10-Q · filed 2023-05-11 | -$17.48M derived: sum of 2 quarters · filed 2023-05-11 | -$9.23M derived: sum of 3 quarters · filed 2023-05-11 | $3.13M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$948.00K derived: sum of 2 quarters · filed 2023-03-30 | $11.42M derived: sum of 3 quarters · filed 2023-03-30 | $11.42M 10-K · filed 2023-03-30 |
| 2021-09-30 | $8.25M 10-Q · filed 2022-11-10 | $20.62M derived: sum of 2 quarters · filed 2022-11-10 | $20.62M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $12.37M 10-Q · filed 2022-08-05 | $12.37M 10-Q · filed 2022-08-05 | ||
| 2020-12-31 | $4.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $4.55M derived: sum of 2 quarters · filed 2022-03-29 | $5.06M derived: sum of 3 quarters · filed 2022-03-29 | $4.61M 10-K · filed 2022-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $507.00K derived: sum of 2 quarters · filed 2021-11-12 | $52.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $507.00K 10-Q · filed 2021-09-08 | $52.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |